Prognostic Impact of MITD1 and Associates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma

被引:7
作者
Chen, Chujie [1 ]
Sheng, Yiyu [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Urol, 628 Zhenyuan Rd, Shenzhen 518017, Peoples R China
关键词
MITD1; KIRC; TCGA; bioinformatics; CD8+T cells; GENE; IDENTIFICATION; MANAGEMENT; PROFILES;
D O I
10.1177/15330338211036233
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Kidney renal clear cell carcinoma (KIRC) is one of the most malignant diseases with poor survival rate over the world. The tumor microenvironment (TME) is highly related to the oncogenesis, development, and prognosis of KIRC. Thus, making the identification of KIRC biomarkers and immune infiltrates critically important. Microtubule Interacting and Trafficking Domain containing 1(MITD1) was reported to participate in cytokinesis of cell division. In the present study, multiple bioinformatics tools and databases were applied to investigate the expression level and clinical value of MITD1 in KIRC. We found that the expression of MITD1 was significantly increased in KIRC tissues. Further, the KIRC patients with high MITD1 levels showed a worse overall survival (OS) rate and disease free survival (DFS) rate. Otherwise, we found a significant correlation MITD1 expression and the abundance of CD8+ T cells. Functional enrichment analyses revealed that immune response and cytokine-cytokine receptor are very critical signaling pathways which associated with MITD1 in KIRC. In conclusion, our findings indicated that MITD1 may be a potential biomarker and associated with immune infiltration in KIRC.
引用
收藏
页数:9
相关论文
共 39 条
[1]   Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions [J].
Atkins, M. B. ;
Clark, J. I. ;
Quinn, D. I. .
ANNALS OF ONCOLOGY, 2017, 28 (07) :1484-1494
[2]   Treatment of renal cell carcinoma: Current status and future directions [J].
Barata, Pedro C. ;
Rini, Brian I. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :507-524
[3]   Papillary renal cell carcinoma: A review of the current therapeutic landscape [J].
Courthod, Giulia ;
Tucci, Marcello ;
Di Maio, Massimo ;
Scagliotti, Giorgio V. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (01) :100-112
[4]  
Delahunt B, 1997, MODERN PATHOL, V10, P537
[5]   CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review [J].
Farhood, Bagher ;
Najafi, Masoud ;
Mortezaee, Keywan .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (06) :8509-8521
[6]   A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma [J].
Fernandez-Pello, Sergio ;
Hofmann, Fabian ;
Tahbaz, Rana ;
Marconi, Lorenzo ;
Lam, Thomas B. ;
Albiges, Laurence ;
Bensalah, Karim ;
Canfield, Steven E. ;
Dabestani, Saeed ;
Giles, Rachel H. ;
Hora, Milan ;
Kuczyk, Markus A. ;
Merseburger, Axel S. ;
Powles, Thomas ;
Staehler, Michael ;
Volpe, Alessandro ;
Ljungberg, Borje ;
Bex, Axel .
EUROPEAN UROLOGY, 2017, 71 (03) :426-436
[7]   Recent progress in the management of advanced renal cell carcinoma [J].
Garcia, Jorge A. ;
Rini, Brian I. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (02) :112-125
[8]   Immunity, Inflammation, and Cancer [J].
Grivennikov, Sergei I. ;
Greten, Florian R. ;
Karin, Michael .
CELL, 2010, 140 (06) :883-899
[9]   ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes [J].
Hornung, Tassilo ;
O'Neill, Heather A. ;
Logie, Stephen C. ;
Fowler, Kimberly M. ;
Duncan, Janet E. ;
Rosenow, Matthew ;
Bondre, Aniket S. ;
Tinder, Teresa ;
Maher, Varun ;
Zarkovic, Jelena ;
Zhong, Zenyu ;
Richards, Melissa N. ;
Wei, Xixi ;
Miglarese, Mark R. ;
Mayer, Gunter ;
Famulok, Michael ;
Spetzler, David .
NUCLEIC ACIDS RESEARCH, 2020, 48 (08) :4013-4027
[10]   Renal cell carcinoma [J].
Hsieh, James J. ;
Purdue, Mark P. ;
Signoretti, Sabina ;
Swanton, Charles ;
Albiges, Laurence ;
Schmidinger, Manuela ;
Heng, Daniel Y. ;
Larkin, James ;
Ficarra, Vincenzo .
NATURE REVIEWS DISEASE PRIMERS, 2017, 3